A first-in-human study of FT516 to evaluate the safety and tolerability of multiple dosing cycles of FT516 in combination with FDA-approved monoclonal antibody therapy.
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
At a glance
- Drugs FT-516 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- 22 Mar 2018 New trial record